Mode
Text Size
Log in / Sign up

Narrative review explores nesfatin-1 in infertility, pregnancy, and lactationNesfatin-1 May Explain Infertility, Pregnancy Problems, and Milk Supply

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret nesfatin-1 levels cautiously in reproductive conditions due to heterogeneous findings and assay variability.

This narrative review synthesizes current evidence on the adipokine nesfatin-1 in the context of infertility, pregnancy complications, and lactation. The authors highlight that clinical studies in these areas report heterogeneous findings, with nesfatin-1 levels described as increased, decreased, or unchanged across similar clinical conditions. This variability underscores the complexity of nesfatin-1's role in reproductive physiology.

Key limitations identified include assay variability, timing of sampling, and population heterogeneity, which may contribute to the inconsistent results. The authors caution against interpreting nesfatin-1 as a straightforward biomarker, emphasizing that it should be viewed as a context-dependent endocrine integrator.

The review does not provide pooled effect sizes or meta-analytic data, as it is a narrative synthesis. No specific interventions, comparators, or outcomes are reported. The practice relevance is not explicitly stated, but the findings suggest that clinical application of nesfatin-1 measurement remains uncertain due to the lack of consistent evidence.

Overall, this review underscores the need for standardized methodologies and larger, well-controlled studies to clarify nesfatin-1's potential role in reproductive health. Clinicians should interpret current data cautiously, recognizing the limitations and heterogeneity in the literature.

A single chemical in your body may act like a bridge between stress, metabolism, and reproduction. It is called nesfatin-1. New research suggests this chemical could help explain why some people struggle with infertility, face pregnancy complications, or have trouble making enough milk after birth.

This matters because these problems are common and deeply personal. Infertility affects millions of people worldwide. Pregnancy complications like gestational diabetes and preeclampsia can put both mother and baby at risk. Low milk supply can cause stress and early weaning. Current treatments often focus on one system at a time, but the body does not work in separate boxes. Stress, weight, and hormones are tightly connected.

But here is the twist. Nesfatin-1 does not act the same way in every person or every situation. It can rise or fall depending on your metabolic health, stress level, inflammation, and reproductive stage. That makes it hard to pin down as a simple biomarker. Instead, it may work as a context-dependent integrator, a signal that reflects how multiple body systems are talking to each other.

Think of nesfatin-1 like a traffic controller at a busy intersection. It helps direct signals between the brain, fat tissue, the stress axis, and the reproductive system. When traffic flows smoothly, energy balance, stress response, and fertility align. When there is a jam, the controller shifts priorities, which can affect ovulation, pregnancy, or milk production.

Nesfatin-1 is made from a larger protein called nucleobindin-2. It is found in the brain and in many tissues throughout the body. It helps regulate appetite and energy use. It also interacts with the stress hormone axis and inflammatory pathways. These roles make it a strong candidate for linking metabolic and reproductive health.

The review in Frontiers in Medicine looked at human studies across the reproductive life course. Researchers examined evidence on infertility, assisted reproductive technologies, pregnancy adaptations and complications, the maternal-fetal interface, lactation, and postpartum metabolic recovery. They also looked at where nesfatin-1 appears in the body, including maternal blood, follicular fluid, amniotic fluid, cord blood, and breast milk.

Here is what they found. Studies report inconsistent results. In some conditions, nesfatin-1 levels are higher. In others, they are lower. In some cases, there is no change. This variability is not a flaw in the research. It likely reflects real biology. Nesfatin-1 responds to metabolic status, stress-axis activation, inflammation, and reproductive stage. It is a moving target, not a fixed number.

This does not mean this treatment is available yet.

In infertility, nesfatin-1 has been measured in blood and follicular fluid from people undergoing assisted reproductive technologies. Some studies link higher levels to better outcomes, while others show the opposite. The pattern may depend on body weight, insulin resistance, or stress levels. In pregnancy, nesfatin-1 appears in amniotic fluid and cord blood. It may play a role in placental function and fetal growth. In gestational diabetes and preeclampsia, results are mixed, but the chemical seems to reflect metabolic and inflammatory changes.

In lactation, nesfatin-1 has been detected in human breast milk. This raises the possibility that it influences milk production or composition. Postpartum metabolic recovery also involves nesfatin-1, as the body shifts from pregnancy to lactation and beyond. Again, the direction of change depends on context.

An expert perspective from the review emphasizes that nesfatin-1 should be viewed as an integrative endocrine signal, not a simple biomarker. It reflects the interaction of metabolic, stress-related, inflammatory, and reproductive axes. This framework helps explain why studies report different findings. It also guides future research toward more precise questions.

What this means for you is practical but cautious. If you are dealing with infertility, pregnancy complications, or lactation challenges, nesfatin-1 is not a test your doctor can order today. It is an area of active research. If you are curious, talk to your health care provider about the full picture of your metabolic and reproductive health. Stress management, nutrition, and sleep may influence these pathways in ways that support fertility and pregnancy.

The review also highlights methodological challenges. Assay variability can affect how nesfatin-1 is measured. Timing of sampling matters, since levels can change across the day and across reproductive stages. Population differences, including age, weight, and ethnicity, can also shape results. Future studies need standardized methods and larger, diverse groups.

What happens next is clear. Researchers need to clarify the physiological role of nesfatin-1 in humans. They should test whether it can serve as a longitudinal or stratification biomarker, meaning it could help track changes over time or group people by risk. Clinical trials may explore whether targeting nesfatin-1 pathways improves fertility, pregnancy outcomes, or lactation. For now, this research offers a promising lens for understanding how stress, metabolism, and reproduction are connected.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
Nesfatin-1, a peptide derived from nucleobindin-2 (NUCB2), is a widely expressed neuroendocrine factor originally identified for its anorexigenic effects in the central nervous system. Beyond energy homeostasis, accumulating evidence implicates nesfatin-1 in the regulation of glucose metabolism, stress-axis activity, inflammation, and reproductive function. These properties make nesfatin-1 particularly relevant to human reproduction and early life, physiological states characterized by profound metabolic and endocrine adaptations. The objective of this review is to examine whether nesfatin-1 functions as an integrative endocrine signal linking metabolic, stress-related, and reproductive pathways across the reproductive life course. We synthesize current human evidence on nesfatin-1 in infertility, assisted reproductive technologies, pregnancy adaptations and complications, the maternal–fetal interface, lactation, and postpartum metabolic recovery. Nesfatin-1 has been detected in several biological compartments relevant to reproductive physiology, including maternal plasma, follicular fluid, amniotic fluid, cord blood, and human breast milk. Clinical studies investigating these compartments report heterogeneous findings, with nesfatin-1 levels described as increased, decreased, or unchanged across similar clinical conditions. This variability likely reflects the context-dependent regulation of nesfatin-1 by metabolic status, stress-axis activation, inflammatory signaling, and reproductive stage. In this review, we synthesize current human evidence on nesfatin-1 across the continuum of reproduction, pregnancy, early development, and lactation, and propose a framework to reconcile these inconsistent findings. We argue that nesfatin-1 should be viewed as a context-dependent endocrine integrator reflecting the interaction of metabolic, stress-related, inflammatory, and reproductive axes rather than as a unidirectional biomarker. We further highlight key methodological challenges, including assay variability, timing of sampling, and population heterogeneity, and discuss the potential of nesfatin-1 as a longitudinal or stratification biomarker in reproductive endocrinology. Finally, we outline priorities for future research to clarify its physiological role and translational relevance in human reproduction and early life.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.